Loading the comparison…
Loading the comparison…
Immune
The human body's own antimicrobial peptide, cut from cathelicidin.
Immune
A three-amino-acid anti-inflammatory fragment of α-MSH.
LL-37 is not FDA-approved and rated 3/5 for evidence; KPV is not FDA-approved and rated 2/5. LL-37 has more human evidence behind it. Both are banned in sport by WADA. Both are used for immune goals.
| Compare | LL-37 The human body's own antimicrobial peptide, cut from cathelicidin. | KPV A three-amino-acid anti-inflammatory fragment of α-MSH. |
|---|---|---|
| Category | Immune | Immune |
| Evidence | 3/5Small human trials of topical LL-37 for venous leg ulcers; a larger Phase IIb missed its overall goal. No human data for injection. | 2/5Cell and mouse colitis studies (e.g. Dalmasso 2008, Gastroenterology). No published human trials. |
| FDA status | Not FDA-approved | Not FDA-approved |
| WADA (sport) | Banned | Banned |
| Also known as | Cathelicidin, hCAP-18 fragment, Ropocamptide | Lys-Pro-Val, α-MSH (11–13) |
| How it works | A positively charged peptide that disrupts microbe membranes and breaks up biofilms. It also signals immune cells and supports wound closure. The same immune-activating effect is linked to psoriasis, rosacea and lupus when it is overactive. | Gets into gut-lining and immune cells through the PepT1 transporter and dampens the NF-κB and MAP-kinase inflammation pathways. Unlike full α-MSH, its anti-inflammatory effect in gut cells does not appear to run through melanocortin receptors, so it is not a tanning peptide. |
| Half-life | Not established in humans; broken down quickly by proteases | Not characterized in humans |
| Commonly reported doses |
|
|
| Route | Subcutaneous | Subcutaneous |
| Good once mixed | ~28 days in the fridge | ~28 days in the fridge |
| Top side effects |
|
|
| Lowest research-listing price per mg | $4.20 (5 mg vial, 40% off) | $2.40 (10 mg vial, 40% off) |
| Latest lab purity | 99.68% (lot LL0002) | 99.36% (lot KPV0002) |
Want a third? Add another peptide. Doses are commonly reported ranges, not recommendations.
Free for ChatGPT and Claude
Connect MyPeps to ChatGPT or Claude and ask follow-ups about LL-37 and KPV. It answers from these same pages, with links back here.
LL-37 is not FDA-approved and rated 3/5 for evidence; KPV is not FDA-approved and rated 2/5. LL-37 has more human evidence behind it. Both are banned in sport by WADA. Both are used for immune goals.
LL-37: Not FDA-approved. KPV: Not FDA-approved. Regulations change, so confirm with the FDA.
LL-37 is rated 3 out of 5: Small human trials of topical LL-37 for venous leg ulcers; a larger Phase IIb missed its overall goal. No human data for injection. KPV is rated 2 out of 5: Cell and mouse colitis studies (e.g. Dalmasso 2008, Gastroenterology). No published human trials. The scale is explained on our methodology page.
LL-37 is banned by WADA, by name or as part of a named class. KPV is banned by WADA, by name or as part of a named class.